卡培他滨 T1408

Product Introduction
Bioactivity


英文名: Capecitabine

描述: Capecitabine (Capecitibine) 是一种可口服的前药，可由胸苷磷酸化酶催化转变为其活性代谢物 Fluorouracil。

细胞实验: HepG2 and either LS174T WT or LS174T-c2 cells are seeded, respectively, in the top and bottom chambers of 8-well strip membranes in 96-well plates. The exponentially growing cells are exposed to increasing concentrations of capecitabine. The medium is supplemented with 750 ng/mL ZB4 MoAB or 100 ng/mL BR17 MoAB when the latter are used in the experiments. After 72 hours of continuous exposure, LS174T viability is assessed using the classic colorimetric MTT test.(Only for Reference)

体外活性: 作用于高肝转移裸鼠时,Capecitabine对肿瘤生长和转移复发的人肝细胞癌均有抑制作用,这是因为血小板驱动的内皮细胞生长因子在肿瘤中高表达.与5-FU,UFT及其中间代谢物5'-DFUR相比,Capecitabine对人类移植瘤更具有广泛的抗癌活谱性,这与肿瘤dThdPase水平相关.

体内活性: Capecitabine以Fas依赖性地方式诱导凋亡,且对胸苷磷酸化酶-转染的LS174T-c2 细胞的毒性强7倍、凋亡更明显。培养在与HepG2细胞相同的板中时,LS174TWT和 LS174T-c2细胞对Capecitabine敏感性的较强,Capecitabine与LS174TWT单独培养时的IC50为890 μM,与HepG2一起培养的IC50为630 μM。此外, LS174T-C2亚型培养在和HepG2相同的板中时, IC50从330±4降至89±6 μM。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: 5% DMSO+95% Saline : 1.8 mg/mL (5 mM)
Ethanol : 35.9 mg/mL (100 mM)
DMSO : 35.9 mg/mL (100 mM)


关键字: inhibit | Nucleoside Antimetabolite/Analog | Capecitabine | Inhibitor | Apoptosis | DNA/RNA Synthesis

相关产品: (20S)-Protopanaxatriol | HO-3867 | 2,5-dimethyl Celecoxib | AOH1160 | Suramin Sodium Salt | Fludarabine Phosphate | GSK2256098 | Isovalerylcarnitine | Embelin | Cholesteryl Hemisuccinate

相关库: Drug Repurposing Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | EMA Approved Drug Library | Anti-Cardiovascular Disease Compound Library

卡培他滨 T1408信息由TargetMol中国为您提供，如您想了解更多关于卡培他滨 T1408报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途